Table VII.
Mean ± standard deviation | |||||
---|---|---|---|---|---|
Variable | CTL group | PRP group | PRP + SC group | Kruskal-Wallis P-value | Kruskall Wallis post-hoc multiple comparison with Bonferroni's correction P-value |
Tissue morphology | 3.10±0.32 | 3.78±0.44 | 4.0±0.00 | 0.003a | aCTL × PRP, P=0.036 |
aCTL × PRP+SC, P=0.004 | |||||
PRP × PRP+SC, P=1.000 | |||||
Matrix staining | 2.90±0.32 | 3.89±0.33 | 3.75±0.46 | 0.002a | aCTL × PRP, P=0.002 |
aCTL × PRP+SC, P=0.017 | |||||
PRP × PRP+SC, P=1.000 | |||||
Structural integrity | 3.30±0.95 | 4.22±0.67 | 4.38±0.52 | 0.020a | CTL × PRP, P=0.163 |
CTL × PRP+SC, P=0.073 | |||||
PRP × PRP+SC, P=1.000 | |||||
Chondrocyte clustering in implant | 1.80±0.42 | 2.00±0.50 | 2.63±0.52 | 0.007a | CTL × PRP, P=1.000 |
aCTL × PRP+SC, P=0.032 | |||||
PRP × PRP+SC, P=0.172 | |||||
Intactness of calcified layer, formation of tidemark | 1.30±0.48 | 2.67±1.12 | 2.25±0.71 | 0.005a | aCTL × PRP, P=0.013 |
CTL × PRP+SC, P=0.069 | |||||
PRP × PRP+SC, P=1.000 | |||||
Subchondral bone formation | 2.20±0.42 | 2.89±0.33 | 2.88±0.35 | 0.002a | aCTL × PRP, P=0.032 |
aCTL × PRP+SC, P=0.046 | |||||
PRP × PRP+SC, P=1.000 | |||||
Histological assessment of surface architecture | 1.70±0.48 | 2.89±0.78 | 3.38±0.52 | <0.001a | aCTL × PRP, P=0.021 |
aCTL × PRP+SC, P=0.001 | |||||
PRP × PRP+SC, P=0.816 | |||||
Histological assessment of defect filling | 4.80±0.42 | 5.00±0.00 | 5.00±0.00 | 0.171 | – |
Lateral integration of implanted material | 2.20±0.42 | 2.22±0.44 | 2.50±0.53 | 0.335 | – |
Basal integration of implanted material | 3.80±0.42 | 3.89±0.33 | 3.25±0.46 | 0.013a | CTL × PRP, P=1.000 |
CTL × PRP+SC, P=0.146 | |||||
PRP × PRP+SC, P=0.076 | |||||
Inflammation maximum total score | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.000 | – |
Total score | 28.10±2.56 | 34.44±3.88 | 35.00±2.27 | 0.001a | aCTL × PRP, P=0.008 |
aCTL × PRP+SC, P=0.002 | |||||
PRP × PRP+SC, P=1.000 |
P<0.05. CTL, control group without treatment; PRP, group treated with platelet-rich plasma; PRP + SC, group treated with platelet-rich plasma plus human dental pulp stem cells.